TABLE OF CONTENTS
1 INTRODUCTION 43
1.1 OBJECTIVES OF THE STUDY 43
1.2 MARKET DEFINITION 43
1.3 OVERVIEW OF GLOBAL BONE MARROW BIOPSY MARKET 43
1.4 CURRENCY AND PRICING 45
1.5 LIMITATIONS 45
1.6 MARKETS COVERED 46
2 MARKET SEGMENTATION 49
2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 DBMR TRIPOD DATA VALIDATION MODEL 52
2.5 MULTIVARIATE MODELLING 56
2.6 PRODUCT TYPE LIFELINE CURVE 56
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 57
2.8 DBMR MARKET POSITION GRID 58
2.9 VENDOR SHARE ANALYSIS 59
2.10 SECONDARY SOURCES 60
2.11 ASSUMPTIONS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 65
5 MARKET OVERVIEW 67
5.1 DRIVERS 69
5.1.1 INCREASING PREVALENCE OF CHRONIC DISEASE SPECIALLY CANCER 69
5.1.2 INCREASING DIAGNOSIS RATE OF EARLY DETECTION 69
5.1.3 ADEQUATE REIMBURSEMENT POLICIES 70
5.1.4 INCREASING AWARENESS PROGRAM AND INITIATIVE 71
5.2 RESTRAINTS 72
5.2.1 HIGH COST OF BONE MARROW BIOPSY TESTING 72
5.2.2 STRINGENT REGULATORY FRAMEWORK AND GUIDELINES 72
5.3 OPPORTUNITIES 73
5.3.1 EXTENSIVE RESEARCH AND DEVELOPMENT ACTIVITIES 73
5.3.2 INTRODUCTION OF CUTTING EDGE BIOPSY DEVICES 73
5.3.3 HUGE MARKET POTENTIAL IN DEVELOPING COUNTRIES 73
?
5.4 CHALLENGES 74
5.4.1 LACK OF MEDICAL INFRASTRUCTURE IN DEVELOPING COUNTRIES 74
5.4.2 SIDE EFFECTS AND RISKS ASSOCIATED WITH BONE MARROW BIOPSY 74
5.4.3 SHORTAGE OF SKILLED PHYSICIAN 75
6 GLOBAL BONE MARROW BIOPSY MARKET, BY PRODUCT TYPE 76
6.1 OVERVIEW 77
6.2 NEEDLES 80
6.2.1 BY TYPE 80
6.2.1.1 JAMSHIDI NEEDLE 81
6.2.1.2 TREPHINE BIOPSY NEEDLES 81
6.2.1.3 SALAH BONE MARROW ASPIRATION NEEDLE 81
6.2.1.4 KLIMA STERNAL NEEDLE 81
6.2.2 BY MODALITY 81
6.2.2.1 DISPOSABLE 81
6.2.2.2 REUSABLE 81
6.2.3 BY ERGONOMICS 81
6.2.3.1 SHARP 82
6.2.3.2 CHIBA 82
6.2.3.3 FRANSEEN 82
6.2.3.4 QUINCKE 82
6.2.3.5 BLUNT 82
6.2.3.6 OTHERS 82
6.3 INSTRUMENTS 83
6.3.1 ANALYZER 83
6.3.2 FLOW CYTOMETER 83
6.3.3 PCR MACHINE 83
6.3.4 OTHERS 83
6.4 BIOPSY GUN 84
6.5 PROCEDURE TRAYS 84
6.6 OTHERS 85
7 GLOBAL BONE MARROW BIOPSY MARKET, BY PROCEDURE TYPE 86
7.1 OVERVIEW 87
7.2 HIP BIOPSY 90
7.3 BREASTBONE (STERNUM) BIOPSY 90
7.4 PERCUTANEOUS TREPHINE BIOPSY 91
7.5 TIBIA (SHIN) BIOPSY 91
7.6 OTHERS 92
?
8 GLOBAL BONE MARROW BIOPSY MARKET, BY BIOPSY TYPE 93
8.1 OVERVIEW 94
8.2 CORE NEEDLE BIOPSY 97
8.3 VACUUM-ASSISTED BIOPSY (VAB) 97
8.4 FINE NEEDLE ASPIRATION BIOPSY 98
9 GLOBAL BONE MARROW BIOPSY MARKET, BY SITE 99
9.1 OVERVIEW 100
9.2 POSTERIOR ILIAC CREST 103
9.3 ANTERIOR ILIAC CREST 103
9.4 CALCANEUS 104
9.5 DISTAL TIBIA 104
9.6 PROXIMAL TIBIA 105
9.7 PROXIMAL HUMERUS 105
9.8 OTHERS 106
10 GLOBAL BONE MARROW BIOPSY MARKET, BY TECHNIQUE 107
10.1 OVERVIEW 108
10.2 FLOW CYTOMETRY 111
10.3 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 111
10.4 POLYMERASE CHAIN REACTION (PCR) 112
10.5 KARYOTYPE TEST 112
10.6 OTHERS 113
11 GLOBAL BONE MARROW BIOPSY MARKET, BY AGE 114
11.1 OVERVIEW 115
11.2 GERIATRIC 118
11.3 ADULT 118
11.4 PEDIATRIC 119
12 GLOBAL BONE MARROW BIOPSY MARKET, BY APPLICATION 120
12.1 OVERVIEW 121
12.2 LYMPHOMA DISEASE 124
12.3 LEUKEMIA 124
12.3.1 CHRONIC LYMPHOCYTIC LEUKEMIA 125
12.3.2 ACUTE MYELOID LEUKEMIA 125
12.3.3 CHRONIC MYELOID LEUKEMIA 125
12.3.4 ACUTE LYMPHOCYTIC LEUKEMIA 125
12.4 POLYCYTHEMIA VERA 125
12.5 MULTIPLE MYELOMA 126
12.6 THROMBOCYTHEMIA 126
12.7 MYELOFIBROSIS 127
12.8 APLASTIC ANEMIA 127
12.9 OTHERS 128
13 GLOBAL BONE MARROW BIOPSY MARKET, BY END USER 129
13.1 OVERVIEW 130
13.2 HOSPITALS 133
13.3 DIAGNOSTIC CENTERS 133
13.4 AMBULATORY SURGICAL CENTERS 134
13.5 ACADEMIC AND RESEARCH ORGANIZATIONS 134
13.6 OTHERS 135
14 GLOBAL BONE MARROW BIOPSY MARKET, BY DISTRIBUTION CHANNEL 136
14.1 OVERVIEW 137
14.2 DIRECT TENDER 140
14.3 RETAIL SALES 140
15 GLOBAL BONE MARROW BIOPSY MARKET, BY GEOGRAPHY 141
15.1 OVERVIEW 142
15.2 NORTH AMERICA 148
15.2.1 U.S. 157
15.2.2 CANADA 162
15.2.3 MEXICO 167
15.3 EUROPE 172
15.3.1 GERMANY 182
15.3.2 FRANCE 187
15.3.3 U.K. 192
15.3.4 ITALY 197
15.3.5 SPAIN 202
15.3.6 NETHERLANDS 207
15.3.7 SWITZERLAND 212
15.3.8 BELGIUM 217
15.3.9 RUSSIA 222
15.3.10 TURKEY 227
15.3.11 REST OF EUROPE 232
15.4 ASIA-PACIFIC 233
15.4.1 CHINA 243
15.4.2 JAPAN 248
15.4.3 INDIA 253
15.4.4 SOUTH KOREA 258
15.4.5 AUSTRALIA 263
15.4.6 INDONESIA 268
15.4.7 THAILAND 273
15.4.8 MALAYSIA 278
15.4.9 SINGAPORE 283
15.4.10 PHILIPPINES 288
15.4.11 REST OF ASIA-PACIFIC 293
15.5 SOUTH AMERICA 294
15.5.1 BRAZIL 303
15.5.2 ARGENTINA 308
15.5.3 REST OF SOUTH AMERICA 313
15.6 MIDDLE EAST AND AFRICA 314
15.6.1 SOUTH AFRICA 323
15.6.2 SAUDI ARABIA 328
15.6.3 U.A.E 333
15.6.4 ISRAEL 338
15.6.5 EGYPT 343
15.6.6 REST OF MIDDLE EAST AND AFRICA 348
16 GLOBAL BONE MARROW BIOPSY MARKET, COMPANY LANDSCAPE 349
16.1 COMPANY SHARE ANALYSIS: GLOBAL 349
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 350
16.3 COMPANY SHARE ANALYSIS: EUROPE 351
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 352
17 GLOBAL BONE MARROW BIOPSY MARKET: SWOT ANALYSIS 353
17.1 SWOT ANALYSIS 353
17.1.1 STRENGTH: - WIDE PRODUCT PORTFOLIO 353
17.1.2 STRENGTH: - STRONG GLOBAL PRESENCE 353
17.1.3 STRENGTH: - EXTENSIVE RESEARCH AND DEVELOPMENT ACTIVITIES 354
17.1.4 WEAKNESS: - SINGLE SUPPLIER 354
17.1.5 WEAKNESS: - PRODUCT RECALL 355
17.1.6 WEAKNESS: - OBSOLETE TECHNOLOGIES 355
17.1.7 OPPORTUNITY: - EXPANDING BUSINESS THOROUGH THEIR SUBSIDIARIES 355
17.1.8 OPPORTUNITY: - ACQUISITION 356
17.1.9 THREAT: - FDA STANDARDS/ REGULATORY AUTHORITIES STRINGENT RULES 356
17.2 DATA BRIDGE MARKET RESEARCH ANALYSIS 356
?
18 COMPANY PROFILE 357
18.1 BD 357
18.1.1 COMPANY SNAPSHOT 357
18.1.2 REVENUE ANALYSIS 358
18.1.3 COMPANY SHARE ANALYSIS 358
18.1.4 PRODUCT PORTFOLIO 359
18.1.5 RECENT DEVELOPMENT 359
18.2 MEDTRONIC 360
18.2.1 COMPANY SNAPSHOT 360
18.2.2 REVENUE ANALYSIS 361
18.2.3 COMPANY SHARE ANALYSIS 361
18.2.4 PRODUCT PORTFOLIO 362
18.2.5 RECENT DEVELOPMENT 362
18.3 ARGON MEDICAL 363
18.3.1 COMPANY SNAPSHOT 363
18.3.2 COMPANY SHARE ANALYSIS 363
18.3.3 PRODUCT PORTFOLIO 363
18.3.4 RECENT DEVELOPMENT 364
18.4 MERIT MEDICAL SYSTEMS 365
18.4.1 COMPANY SNAPSHOT 365
18.4.2 REVENUE ANALYSIS 366
18.4.3 COMPANY SHARE ANALYSIS 366
18.4.4 PRODUCT PORTFOLIO 367
18.4.5 RECENT DEVELOPMENTS 367
18.5 CARDINAL HEALTH 368
18.5.1 COMPANY SNAPSHOT 368
18.5.2 REVENUE ANALYSIS 369
18.5.3 COMPANY SHARE ANALYSIS 369
18.5.4 PRODUCT PORTFOLIO 370
18.5.5 RECENT DEVELOPMENT 370
18.6 TELEFLEX INCORPORATED 371
18.6.1 COMPANY SNAPSHOT 371
18.6.2 REVENUE ANALYSIS 372
18.6.3 PRODUCT PORTFOLIO 372
18.6.4 RECENT DEVELOPMENT 372
18.7 BIOMEDICAL SRL 373
18.7.1 COMPANY SNAPSHOT 373
18.7.2 PRODUCT PORTFOLIO 373
18.7.3 RECENT DEVELOPMENT 373
18.8 BPB MEDICA 374
18.8.1 COMPANY SNAPSHOT 374
18.8.2 PRODUCT PORTFOLIO 374
18.8.3 RECENT DEVELOPMENT 374
18.9 COOK 375
18.9.1 COMPANY SNAPSHOT 375
18.9.2 PRODUCT PORTFOLIO 375
18.9.3 RECENT DEVELOPMENT 376
18.10 EGEMEN INTERNATIONAL 377
18.10.1 COMPANY SNAPSHOT 377
18.10.2 PRODUCT PORTFOLIO 377
18.10.3 RECENT DEVELOPMENT 377
18.11 HIPROVE 378
18.11.1 COMPANY SNAPSHOT 378
18.11.2 PRODUCT PORTFOLIO 378
18.11.3 RECENT DEVELOPMENT 378
18.12 JORGENSEN LABS 379
18.12.1 COMPANY SNAPSHOT 379
18.12.2 PRODUCT PORTFOLIO 379
18.12.3 RECENT DEVELOPMENT 379
18.13 MEDICAL DEVICES BUSINESS SERVICES, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 380
18.13.1 COMPANY SNAPSHOT 380
18.13.2 REVENUE ANALYSIS 381
18.13.3 PRODUCT PORTFOLIO 381
18.13.4 RECENT DEVELOPMENT 381
18.14 MDL SRL 382
18.14.1 COMPANY SNAPSHOT 382
18.14.2 PRODUCT PORTFOLIO 382
18.14.3 RECENT DEVELOPMENT 382
18.15 SHANGHAI MEKON MEDICAL DEVICES CO., LTD. 383
18.15.1 COMPANY SNAPSHOT 383
18.15.2 PRODUCT PORTFOLIO 383
18.15.3 RECENT DEVELOPMENT 383
18.16 SOMATEX MEDICAL TECHNOLOGIES GMBH 384
18.16.1 COMPANY SNAPSHOT 384
18.16.2 PRODUCT PORTFOLIO 384
18.16.3 RECENT DEVELOPMENT 384
?
18.17 STERYLAB S.R.L. 385
18.17.1 COMPANY SNAPSHOT 385
18.17.2 PRODUCT PORTFOLIO 385
18.17.3 RECENT DEVELOPMENT 385
18.18 TSUNAMI MEDICAL SRL 386
18.18.1 COMPANY SNAPSHOT 386
18.18.2 PRODUCT PORTFOLIO 386
18.18.3 RECENT DEVELOPMENT 386
18.19 WELLGO MEDICAL PRODUCTS GMBH 387
18.19.1 COMPANY SNAPSHOT 387
18.19.2 PRODUCT PORTFOLIO 387
18.19.3 RECENT DEVELOPMENT 387
18.20 ZAMAR CARE 388
18.20.1 COMPANY SNAPSHOT 388
18.20.2 PRODUCT PORTFOLIO 388
18.20.3 RECENT DEVELOPMENT 388
19 QUESTIONNAIRE 389
20 CONCLUSION 394
21 RELATED REPORTS 395